{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:38:46Z","timestamp":1790487526138,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with recurrent adult T\u2010cell leukemia\/lymphoma (ATL) after allogeneic hematopoietic cell transplantation (allo\u2010HCT) have a dismal prognosis. We retrospectively evaluated the safety and efficacy of lenalidomide (LEN)\u00a0in 11 consecutive patients with recurrent ATL after allo\u2010HCT. The median time from allo\u2010HCT to ATL recurrence was 111\u00a0days (range, 20\u20131476), and that from allo\u2010HCT to the initiation of LEN was 162\u00a0days (range, 43\u20131560). The median initial daily dose of LEN was 10\u00a0mg (range, 5\u201325), and the median duration of LEN treatment was 37\u00a0days (range, 3\u20131078). Three patients (27%) achieved complete response and two (18%) achieved partial response (PR). The rates of complete or PR according to the involved site were 57% for skin and 50% for nodal or extranodal lesions. With a median follow\u2010up of 1033\u00a0days (range, 601\u20131465) among survivors, the 1\u2010year probability of overall survival (OS) after ATL recurrence was 55%. Grade \u22653 toxicities included cytopenia (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a04), superficial vein thrombosis (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a01), and deep vein thrombosis (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a01). Graft\u2010versus\u2010host disease (GVHD) newly developed in five patients (45%) and worsened in four patients (36%). The median duration from the initiation of LEN to GVHD onset or worsening was 5\u00a0days (range, 1\u20139). GVHD was manageable in all patients. Seven patients received mogamulizumab (MOG) for recurrent ATL before LEN treatment. The overall response rates to LEN were 57% in patients who had previously received MOG and 25% in those who had not. The 1\u2010year probabilities of OS after recurrent ATL were 71% in patients who had previously received MOG and 25% in those who had not. Although cytopenia and GVHD are common among patients with recurrent ATL after allo\u2010HCT, LEN may improve survival. Administering MOG before LEN may augment treatment efficacy in the allo\u2010HCT population.\n                  <\/jats:p>","DOI":"10.1002\/hon.3115","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T22:19:06Z","timestamp":1670969946000},"page":"389-395","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Lenalidomide treatment for recurrent adult T\u2010cell leukemia\/lymphoma after allogeneic hematopoietic cell transplantation"],"prefix":"10.1002","volume":"41","author":[{"given":"Takashi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital  Chuo\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v50.3.481.481"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00501"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02235"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2558"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.3472"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010018\u20100291\u20105"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2712"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.7732"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010019\u201002675\u20101"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010021\u201001432\u20105"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.1991.tb08051.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.18.2428"},{"issue":"6","key":"e_1_2_9_14_1","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067629"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201004\u2010348292"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.04.014"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1427859"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1316796110"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.cir\u201015\u20100303"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.3115","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:27:31Z","timestamp":1691594851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/hon.3115"],"URL":"https:\/\/doi.org\/10.1002\/hon.3115","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.3115\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3115\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3115\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3115\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3115\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.3115\/v2\/review2","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]},"assertion":[{"value":"2022-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}